OrganiGram Holdings, Inc, licensed under the Marihuana for Medical Purposes Regulations (MMPR), is a company that develops, produces, and sells medicinal marijuana in Canada. Though it entered the industry fairly recently, it already produces 16 strains of medical cannabis that are condition-specific, and is in the process of developing more.
Condition-specific cannabis strains, as OrganiGram emphasizes, contain specific formulations of medicinal cannabis compounds CBD and THC to target and treat particular health conditions. Among the conditions targeted by the company’s strains are symptoms and side-effects in patients with anxiety, cancer, HIV/AIDS, muscular dystrophy, spinal cord disease, arthritis, and more.
OrganiGram groups its cannabis strains according to their targets and effects. The groups are: ACN for stimulating appetite and controlling nausea, ASD for reducing anxiety and stress disorders, MCP for managing chronic pain, NDS for addressing neurological disorders including spasticity, and DCQ for providing dignity, comfort, and proper quality of life to end-of-life patients.
The company markets its products to both doctors and patients, selling them through online channels and telephone orders. It was in September 2014 when OrganiGram delivered its first shipment to its registered customers.
OrganiGram Holdings was founded in 2010 under the name Inform Exploration Corp. It was then a resource acquisition and exploration company in Vancouver. Following a reverse takeover, the company became OrganiGram Holdings, Inc in August 2014.
Today, OrganiGram is listed as OGI in the TSX Venture Exchange, and as OGRMF in the US OTC markets. It has a market cap of CAD 20.55 M. It is now also based in New Brunswick.
Key executives at OrganiGram Holdings, Inc are Chairman, President, and CEO Denis Arsenault, Director of Investor Relations Brett Allan, and CFO Scott Franklin.
OrganiGram Holdings, Inc.
35A English Dr.
Moncton, NB E1E 3X3